53
Participants
Start Date
September 28, 2017
Primary Completion Date
December 31, 2019
Study Completion Date
December 31, 2019
NUC-1031 500 mg
NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
NUC-1031 750mg
NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
Florida Cancer Specialists and Research Institute, St. Petersburg
Nashville Tennessee Oncology, Nashville
SCRI - HCA Health Midwest, Kansas City
Texas Oncology - Tyler, Tyler
Texas Oncology The Woodlands, Gynecologic Oncology, The Woodlands
Texas Oncology - South Austin, Austin
Rocky Mountain Cancer Centers, LLP, Lakewood
Arizona Oncology Associates, PC - HAL, Phoenix
Arizona Oncology Associates, PC - HOPE, Tucson
Minnesota Oncology Hematology, P.A., Edina
Edinburgh Cancer Centre, Edinburgh
Cancer Research UK Clinical Trial Unit, Glasgow
St Bartholomew's Hospital, London
University College London Hospital, London
Royal Marsden Hospital, London
Imperial College Healthcare NHS Trust, London
Oxford University Hospital Foundation Trust, Oxford
Lead Sponsor
NuCana plc
OTHER